Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

• ClinicalTrials.gov Identifier: NCT00157196
• Recruitment Status: Completed
• First Posted: September 12, 2005
• Results First Posted: August 18, 2015
• Last Update Posted: August 18, 2015
• Sponsor: Merck KGaA, Darmstadt, Germany
• Information provided by (Responsible Party): Merck KGaA, Darmstadt, Germany

Study Description

Brief Summary:

The primary objective is to document the safety of tecemotide (L-BLP25) phase III formulation in non-small cell lung cancer (NSCLC) subjects with unresectable Stage III disease. This population includes Stage IIIA NSCLC subjects, a population not studied in former clinical studies with this vaccine. The secondary objective is to document the survival of subjects treated.

Condition or disease	Intervention/treatment	Phase
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms	Biological: Tecemotide (L-BLP25); Drug: Single low dose cyclophosphamide; Other: Best standard of care (BSC)	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 22 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Patients With Unresectable Stage III Disease
• Study Start Date: April 2005
• Actual Primary Completion Date: September 2007
• Actual Study Completion Date: April 2012

Arms and Interventions

Arm

Intervention/treatment

Experimental: Tecemotide(L-BLP25)+Cyclophosphomide+best standard of care

Biological: Tecemotide (L-BLP25); After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide [L-BLP25]) at 6-week intervals, commencing at Week 13, until disease progression is documented.; Drug: Single low dose cyclophosphamide; A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.; Other: Best standard of care (BSC); The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs With CALGB-ECTC Grade 3 or 4, TEAEs Leading to Discontinuation, TEAEs Leading to Death, and Injection Site Reactions (ISRs) [ Time Frame: Up to data cut-off date (17 September 2007) ]
   TEAEs occurred between the first dose of study drug and up to 42 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs with Cancer and Leukemia Group B Extended Clinical Toxicity Criteria (CALGB-ECTC) Grade 3 or 4 were also reported.

Secondary Outcome Measures :

1. Survival Time [ Time Frame: Up to data cut-off date (17 September 2007) ]
   Survival time was to be measured from study entry (date of cyclophosphamide administration) to date of death. For subjects alive or lost to follow-up at time of analysis, the time between date of cyclophosphamide administration and date on which the subject was last known alive was to be calculated and used as a censored observation in the analysis.
2. Progression Free Survival (PFS) Time [ Time Frame: Up to data cut-off date (17 September 2007) ]
   PFS was defined as duration from first administration of trial treatment until progressive disease [PD] (radiological or clinical, if radiological progression is not available) or death due to any cause. Participants without event were censored on the date of last tumor assessment. Clinical assessments were performed 4 weekly in primary treatment and 6 weekly in maintenance treatment.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically documented unresectable stage III NSCLC. Mediastinal (N2) involvement must be confirmed by biopsy
• Stable disease or clinical response after primary therapy of chemo-radiation treatment for unresectable stage III disease

• Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic radiation. The combined modality should consist of either:

  • induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy; or
  • concurrent chemo-radiation therapy followed by 2 cycles of consolidation chemotherapy; or
  • concurrent chemoradiation therapy alone
• A minimum radiation dose of greater than or equal to (>=) 6,000 centigray (cGy) should be administered. Subjects must have completed the primary therapy at least 4 weeks and no later than 6 months prior to study entry
• Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (<=) 1
• Ability to understand and willingness to sign a written informed consent
• Other protocol defined inclusion criteria could apply

Exclusion Criteria:

• Undergone lung cancer specific therapy (including surgery) prior to primary chemo-radiation therapy
• Received immunotherapy/systemic immunosuppressive drugs/investigational systemic drugs within 4 weeks prior to study entry
• Subjects with brain metastases, pleural effusion, unless cytologically confirmed to be non-malignant
• Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
• Autoimmune disease or immunodeficiency
• Clinically significant hepatic, renal dysfunction or cardiac diseases
• Clinically significant active infection
• Pregnant or lactating, women of childbearing potential, unless using effective contraception as determined by the investigator
• Other protocol defined inclusion criteria could apply

Contacts and Locations

Sponsors and Collaborators

Merck KGaA, Darmstadt, Germany

Investigators

• Study Director: Medical Responsible; Merck KGaA, Darmstadt, Germany

More Information

Publications of Results:

Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, Goss G, Ely G, Beier F, Soulières D. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2010 Nov 1;11(6):391-5. doi: 10.3816/CLC.2010.n.101.

• Responsible Party: Merck KGaA, Darmstadt, Germany
• ClinicalTrials.gov Identifier: NCT00157196
• Other Study ID Numbers: B25-LG-305 / EMR 63325-006
• First Posted: September 12, 2005
• Results First Posted: August 18, 2015
• Last Update Posted: August 18, 2015
• Last Verified: July 2015

Keywords provided by Merck KGaA, Darmstadt, Germany:

Carcinoma, Non-Small-Cell Lung, L-BLP25, Tecemotide

Additional relevant MeSH terms:

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Diseases; Cyclophosphamide; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists